The FDA has approved the production and use of Choline C 11 Injection, a positron emission tomography (PET) imaging agent used to help detect recurrent prostate cancer (PCa).

In each of four independent studies involving a total of 98 men with elevated PSA levels but no sign of recurrent PCa on conventional imaging, many of the men were found to have recurrent disease after PET imaging with Choline C 11.